A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

Blood

Volumn 102, Issue 5, 2003, Pages 1606-1612

  Press, Oliver W ^a   Unger, Joseph M ^b   Braziel, Rita M ^b   Maloney, David G ^b   Miller, Thomas P ^b   LeBlanc, Michael ^b   Gaynor, Ellen R ^b   Rivkin, Saul E ^b   Fisher, Richard I ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; LUGOL; PARACETAMOL; POTASSIUM IODIDE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TOSITUMOMAB I 131; VINCRISTINE;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CYTOPENIA; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; ENDOCRINE DISEASE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GENITAL SYSTEM DISEASE; HUMAN; IMMUNOTOXICITY; INFECTION; LOW BACK PAIN; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0041440084     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0287     Document Type: Article

References (24)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
2. Horning SJ. Treatment approaches to the low-grade Lymphomas. Blood. 1994;83:881-884.
3. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282-1290.
4. Miller TP, LeBlanc M, Grogan TM, Fisher RI. Follicular lymphomas: do histologic subtypes predict outcome? Hematol Oncol Clin North Am. 1997;11:893-900.
5. Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993;11:644-651.
6. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001;97:404-409.
7. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325:1525-1533.
8. Rohatiner AZ, Gregory W, Peterson B, et al. A meta-analysis of randomised studies evaluating the role of interferon alpha as treatment for follicular lymphoma [abstract]. Proc Am Soc Clin Oncol. 2002;21:264a.
9. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
10. Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002;29:36-40.
11. Maloney DG, Press OW, Braziel RM, et al. A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800 [abstract]. Blood. 2001;98:843a.
12. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
13. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
14. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
15. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942.
16. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
17. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
18. Kaminski MS, Tuck M, Regan D, Kison P, Wahl RL. High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131 tositumomab (Bexxar®) [abstract]. Blood. 2002;100:356a.
19. Kaminski MS, Estes J, Tuck M, et al. Iodine-131-tositumomab therapy for previously untreated follicular lymphoma [abstract]. Proc Am Soc Clin Oncol. 2000;19:5a.
20. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:2454-2460.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
24. Q'Donoghue JA. Optimal therapeutic strategies for radioimmunotherapy. Recent Results Cancer Res. 1996;141:77-99.